Cargando…
PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters
Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death globally, and new immunotherapies developed and under development targeting PD-1/PD-L1 checkpoint inhibition require accurate patient selection to assure good clinical outcome. PD-L1 immunohistochemistry is the current biomarker...
Autores principales: | Silva, Manuel A., Ryall, Karen A., Wilm, Claudia, Caldara, Jenifer, Grote, Hans Juergen, Patterson-Kane, Janet C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991369/ https://www.ncbi.nlm.nih.gov/pubmed/29874226 http://dx.doi.org/10.1371/journal.pone.0196464 |
Ejemplares similares
-
Stromal Filters in Automated Immunostain Scoring
por: Patel, Kunal, et al.
Publicado: (2014) -
Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors
por: Goodman, Simon L., et al.
Publicado: (2012) -
PD−L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2021) -
On immunosurveillance in human cancer.
por: Thomas, L.
Publicado: (1982) -
Correction: PD − L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2022)